← Back to Screener
Nasus Pharma Ltd. (NSRX)
Price$2.86
Favorite Metrics
Price vs S&P 500 (26W)-80.75%
Price vs S&P 500 (4W)-25.60%
Market Capitalization$19.29M
All Metrics
Price vs S&P 500 (YTD)-78.78%
10-Day Avg Trading Volume0.03M
EPS (Annual)$-0.00
Cash / Share (Quarterly)$0.00
ROA (Last FY)-425.00%
Cash Flow / Share (Annual)$-0.00
Net Interest Coverage (TTM)-5.60x
EPS Incl Extra (Annual)$-0.00
Current Ratio (Annual)0.12x
Quick Ratio (Quarterly)0.08x
3-Month Avg Trading Volume0.12M
52-Week High$9.99
EPS Excl Extra (Annual)$-0.00
26-Week Price Return-72.00%
Quick Ratio (Annual)0.08x
13-Week Price Return-69.31%
Current Ratio (Quarterly)0.12x
Cash / Share (Annual)$0.00
3-Month Return Std Dev131.51%
EPS Basic Excl Extra (Annual)$-0.00
Revenue / Share (Annual)$0.00
Year-to-Date Return-75.52%
5-Day Price Return-3.86%
EPS Normalized (Annual)$-0.00
Month-to-Date Return0.90%
EBITD / Share (Annual)$-0.00
Price vs S&P 500 (13W)-72.18%
Beta1.00x
52-Week Low$1.98
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NSRXNasus Pharma Ltd. | — | — | — | — | $2.86 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Nasus Pharma is a clinical-stage specialty pharmaceutical company developing intranasal formulations for acute emergencies, including opioid overdose and anaphylactic shock. Its portfolio includes intranasal naloxone, which has completed pivotal clinical trials, and intranasal epinephrine in phase 2 development, supported by proprietary microsphere technology.